<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375205</url>
  </required_header>
  <id_info>
    <org_study_id>Galderma Cetaphil Restoraderm</org_study_id>
    <nct_id>NCT01375205</nct_id>
  </id_info>
  <brief_title>Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants</brief_title>
  <official_title>A Randomized Pilot Trial Comparing Cetaphil® Restoraderm® System and Standard Skin Care in Infants at Risk for Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine what effect Cetaphil® Restoraderm® system has on
      babies' skin versus Johnson &amp; Johnson baby lotion and skin cleanser.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will randomly be divided into a group using Cetaphil® Restoraderm® system or a group
      using Johnson &amp; Johnson baby lotion and skin cleanser . At 3, 6, and 12 months non-invasive
      measurements of barrier function will be used to test the babies' skin. The procedures are as
      follows:

        -  Transepidermal loss (TEWL - measures the water loss from the skin)

        -  Skin electrical capacitance (measures how much water stays in the top layer of skin)

        -  Skin pH (measures level of pH)

        -  Skin microbiome analysis (skin swabs to check genetic code of skin bacteria)

        -  Lipidomic and natural moisturizing factor analysis (measures lipids (oils) in the top
           layer of skin)

      Both groups will be reminded to follow the instructions about general good skin care of
      infants. Subjects will be asked if they agree to provide a saliva sample. If yes, a saliva
      sample will be collected from the inside of the infant's cheek at the 6 month visit and will
      be shipped to the laboratory of Dr. Irwin McLean at the University of Dundee, where it will
      be tested for gene defects in the skin barrier that might trigger the development of eczema.
      Defects in the gene called filaggrin have been shown to increase the risk of developing
      eczema. The samples will be identified by a code to protect your infant's identity. The
      saliva samples will be stored only for this study, and then the sample will be destroyed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Cumulative Atopic Dermatitis Diagnosed by Investigator at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of cumulative Atopic Dermatitis diagnosed by a blinded investigator at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of High Emollient Use</measure>
    <time_frame>2, 6, 12, 18, and 24 months</time_frame>
    <description>Patient-reported adherence to the emollient regimen in the intervention group and the treatment group. High emollient use was defined as applying the intervention or control emollient five or more days per week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age at Onset of Eczema</measure>
    <time_frame>Baseline through Month 24 Follow-up</time_frame>
    <description>Age of subject at onset of eczema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Filaggrin Mutation Status</measure>
    <time_frame>6 month visit</time_frame>
    <description>Filaggrin mutation status result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transepidermal Water Loss (TEWL)</measure>
    <time_frame>2 month, 6 month, and 12 month visits</time_frame>
    <description>Transepidermal water loss (TEWL) to measure skin barrier function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Hydration (Skin Electrical Capacitance)</measure>
    <time_frame>2 month, 6 month, and 12 month visits</time_frame>
    <description>Determination of stratum corneum hydration from the dorsal forearm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin pH</measure>
    <time_frame>2 month, 6 month, and 12 month visits</time_frame>
    <description>Skin pH, as measured using a pH probe</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetaphil Restoraderm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cetaphil Restoraderm</intervention_name>
    <description>Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.</description>
    <arm_group_label>Cetaphil Restoraderm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Johnson&amp;Johnson</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants up to three weeks of age born to mothers aged 18-45 years will be recruited
             for this study.

          -  Infants must have a family history of asthma, eczema, or hayfever in at least one
             first-degree relative and be in otherwise good overall health.

        Exclusion Criteria:

          -  Preterm birth defined as birth prior to 37 weeks gestation

          -  Major congenital anomaly

          -  Hydrops fetalis

          -  Significant dermatitis at birth not including seborrheic dermatitis on the scalp
             (&quot;cradle cap&quot;)

          -  Any immunodeficiency disorder

          -  Any severe genetic skin disorder

          -  Any other serious condition that would make the use of emollients inadvisable

          -  Any other major medical problems that the investigator deems may increase the risk of
             adverse events with the intervention or in whom assessing the outcomes may be masked
             by the underlying problem or practically very difficult to assess
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Simpson, MD, MCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Center for Health &amp; Healing</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 15, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <results_first_submitted>January 22, 2019</results_first_submitted>
  <results_first_submitted_qc>January 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2019</results_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Eric Simpson</investigator_full_name>
    <investigator_title>M.D., M.C.R.</investigator_title>
  </responsible_party>
  <keyword>atopic dermatitis</keyword>
  <keyword>skin care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cetaphil Restoraderm</title>
          <description>Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Cetaphil Restoraderm: Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care</title>
          <description>Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.
Standard of Care: Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cetaphil Restoraderm</title>
          <description>Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Cetaphil Restoraderm: Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.
Standard of Care: Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Cumulative Atopic Dermatitis Diagnosed by Investigator at 12 Months</title>
        <description>Percentage of cumulative Atopic Dermatitis diagnosed by a blinded investigator at 12 months</description>
        <time_frame>12 months</time_frame>
        <population>Around 28% of subjects enrolled were lost to follow-up by 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Cetaphil Restoraderm</title>
            <description>Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Cetaphil Restoraderm: Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.
Standard of Care: Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cumulative Atopic Dermatitis Diagnosed by Investigator at 12 Months</title>
          <description>Percentage of cumulative Atopic Dermatitis diagnosed by a blinded investigator at 12 months</description>
          <population>Around 28% of subjects enrolled were lost to follow-up by 12 months</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of High Emollient Use</title>
        <description>Patient-reported adherence to the emollient regimen in the intervention group and the treatment group. High emollient use was defined as applying the intervention or control emollient five or more days per week.</description>
        <time_frame>2, 6, 12, 18, and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cetaphil Restoraderm</title>
            <description>Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Cetaphil Restoraderm: Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.
Standard of Care: Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of High Emollient Use</title>
          <description>Patient-reported adherence to the emollient regimen in the intervention group and the treatment group. High emollient use was defined as applying the intervention or control emollient five or more days per week.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of high emollient use at 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of high emollient use at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4"/>
                    <measurement group_id="O2" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of high emollient use at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of high emollient use at 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                    <measurement group_id="O2" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of high emollient use at 24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age at Onset of Eczema</title>
        <description>Age of subject at onset of eczema</description>
        <time_frame>Baseline through Month 24 Follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cetaphil Restoraderm</title>
            <description>Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Cetaphil Restoraderm: Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.
Standard of Care: Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.</description>
          </group>
        </group_list>
        <measure>
          <title>Age at Onset of Eczema</title>
          <description>Age of subject at onset of eczema</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="24"/>
                    <measurement group_id="O2" value="6" lower_limit="0" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Filaggrin Mutation Status</title>
        <description>Filaggrin mutation status result</description>
        <time_frame>6 month visit</time_frame>
        <population>Number of participants analyzed captures only those participants that completed 6 month filaggrin testing. Not all participants noted in the overall participant flow were able to complete filaggrin testing either due to study status (i.e., lost to follow up, withdrawn) or missed visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetaphil Restoraderm</title>
            <description>Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Cetaphil Restoraderm: Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.
Standard of Care: Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.</description>
          </group>
        </group_list>
        <measure>
          <title>Filaggrin Mutation Status</title>
          <description>Filaggrin mutation status result</description>
          <population>Number of participants analyzed captures only those participants that completed 6 month filaggrin testing. Not all participants noted in the overall participant flow were able to complete filaggrin testing either due to study status (i.e., lost to follow up, withdrawn) or missed visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive for Filaggrin Mutation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative for Filaggrin Mutation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transepidermal Water Loss (TEWL)</title>
        <description>Transepidermal water loss (TEWL) to measure skin barrier function</description>
        <time_frame>2 month, 6 month, and 12 month visits</time_frame>
        <population>Number of participants analyzed captures only those participants that completed TEWL testing at all time points. Not all participants noted in the overall participant flow were able to complete TEWL testing either due to study status (i.e., lost to follow up, withdrawn) or missed visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetaphil Restoraderm</title>
            <description>Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Cetaphil Restoraderm: Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.
Standard of Care: Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.</description>
          </group>
        </group_list>
        <measure>
          <title>Transepidermal Water Loss (TEWL)</title>
          <description>Transepidermal water loss (TEWL) to measure skin barrier function</description>
          <population>Number of participants analyzed captures only those participants that completed TEWL testing at all time points. Not all participants noted in the overall participant flow were able to complete TEWL testing either due to study status (i.e., lost to follow up, withdrawn) or missed visits.</population>
          <units>(g/[m2hr])</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average TEWL (g/[m2hr]) at 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="7.1"/>
                    <measurement group_id="O2" value="18.3" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average TEWL (g/[m2hr]) at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="5.6"/>
                    <measurement group_id="O2" value="16.1" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average TEWL (g/[m2hr]) at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="2.3"/>
                    <measurement group_id="O2" value="16.7" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skin Hydration (Skin Electrical Capacitance)</title>
        <description>Determination of stratum corneum hydration from the dorsal forearm</description>
        <time_frame>2 month, 6 month, and 12 month visits</time_frame>
        <population>Number of participants analyzed captures only those participants that completed skin hydration testing at all time points. Not all participants noted in the overall participant flow were able to complete skin hydration testing either due to study status (i.e., lost to follow up, withdrawn) or missed visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetaphil Restoraderm</title>
            <description>Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Cetaphil Restoraderm: Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.
Standard of Care: Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Hydration (Skin Electrical Capacitance)</title>
          <description>Determination of stratum corneum hydration from the dorsal forearm</description>
          <population>Number of participants analyzed captures only those participants that completed skin hydration testing at all time points. Not all participants noted in the overall participant flow were able to complete skin hydration testing either due to study status (i.e., lost to follow up, withdrawn) or missed visits.</population>
          <units>farads</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average capacitance at 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" spread="14.0"/>
                    <measurement group_id="O2" value="53.9" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average capacitance at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" spread="9.8"/>
                    <measurement group_id="O2" value="52.1" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average capacitance at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" spread="12.7"/>
                    <measurement group_id="O2" value="53.7" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skin pH</title>
        <description>Skin pH, as measured using a pH probe</description>
        <time_frame>2 month, 6 month, and 12 month visits</time_frame>
        <population>Number of participants analyzed captures only those participants that completed Skin pH testing at all time points. Not all participants noted in the overall participant flow were able to complete Skin pH testing either due to study status (i.e., lost to follow up, withdrawn) or missed visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetaphil Restoraderm</title>
            <description>Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Cetaphil Restoraderm: Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.
Standard of Care: Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.</description>
          </group>
        </group_list>
        <measure>
          <title>Skin pH</title>
          <description>Skin pH, as measured using a pH probe</description>
          <population>Number of participants analyzed captures only those participants that completed Skin pH testing at all time points. Not all participants noted in the overall participant flow were able to complete Skin pH testing either due to study status (i.e., lost to follow up, withdrawn) or missed visits.</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average pH at 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="0.4"/>
                    <measurement group_id="O2" value="5.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average pH at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="0.6"/>
                    <measurement group_id="O2" value="5.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average pH at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="0.7"/>
                    <measurement group_id="O2" value="5.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percentage of Participants With Cumulative Atopic Dermatitis Diagnosed by Investigator at 24 Months</title>
        <description>Percentage of cumulative Atopic Dermatitis diagnosed by any MD at 24 Months</description>
        <time_frame>24 Months</time_frame>
        <population>Number of participants analyzed captures only those participants still on study at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetaphil Restoraderm</title>
            <description>Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Cetaphil Restoraderm: Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.
Standard of Care: Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cumulative Atopic Dermatitis Diagnosed by Investigator at 24 Months</title>
          <description>Percentage of cumulative Atopic Dermatitis diagnosed by any MD at 24 Months</description>
          <population>Number of participants analyzed captures only those participants still on study at 24 months.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4"/>
                    <measurement group_id="O2" value="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time informed consent is signed through the 24 month study follow-up telephone call.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cetaphil Restoraderm</title>
          <description>Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Cetaphil Restoraderm: Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care</title>
          <description>Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.
Standard of Care: Subjects will apply Johnson&amp;Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&amp;Johnson cleanser.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic Intracranial Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>RSV and Stridor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Baby Acne</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Viral exanthems</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Heat rash/miliaria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diaper dermatitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Seborrheic Dermatitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Bacterial Skin Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Unspecified Transient Rashes</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Rash to Vaccination/Drug Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Irritant Contact Dermatitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Urticarial Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eric Simpson, MD, MCR</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-494-3968</phone>
      <email>simpsone@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

